ArticlePloS one2015

Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients.

Lin L Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.